title: [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin].
authors.affiliation: y_tsubamoto@mb7.skk-net.com
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Tsubamoto
authors.forename: Moritaka
authors.initials: M
authors.lastname: Goto
mesh_terms: D008078:Cholesterol, LDL / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008078:Cholesterol, LDL; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D014280:Triglycerides; C517652:hemoglobin A1c protein, human; C583175:anagliptin